Business
NeuroPace Announces Refocusing of Product Portfolio
-- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 -- -- Maintaining 2025 Revenue Guidance -- -- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR -- MOUNTAIN VIEW, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported that as part of a strategic refocusing of its prod
About this update from Neuropace, Inc.
[{"type":"image","alt":"NeuroPace, Inc.","displaySize":"","headline":null,"caption":"NeuroPace, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":52,"url":"https://media.zenfs.com/en/globenewswire.com/49cad5934d5ea78febfb7e12e9a6509b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5Q0OXhSfgqHpvUIbwQZadQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTczO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/49cad5934d5ea78febfb7e12e9a6509b","width":300,"height":52}},"lazy":false},{"type":"text","content":"-- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 --","length":86,"tagName":"p"},{"type":"text","content":"-- Maintaining 2025 Revenue Guidance --","length":39,"tagName":"p"},{"type":"text","content":"-- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR --","length":126,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported that as part of a strategic refocusing of its product portfolio on its core, differentiated RNS System product line, it is terminating its distribution relationship for SEEG products and will begin winding down the relationship in the fourth quarter of 2025 and continuing through the first quarter of 2026.","length":503,"tagName":"p"},{"type":"text","content":"“While we believe that entering into the exclusive distribution agreement with DIXI Medical three years ago was appropriate for NeuroPace at the time, our core growth strategy today has evolved significantly from when the distribution agreement began. We believe that, beginning in 2026, our goals will be best and most efficiently served by having our commercial team focus its resources on the significant current and expanding opportunities associated with our differentiated RNS System,” commented Joel Becker, NeuroPace Chief Executive Officer. “Our long-range plan includes clinical, product and market development initiatives around RNS therapy. We are already making good progress with our site of service expansion through Project CARE, and the 2026 planned indication expansion into the drug-resistant idiopathic generalized epilepsy population, expansion into ped...